Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer

Doxorubicin (DOX) is widely used against solid tumors. Niosomes are self‐assembled nanocarriers of non‐ionic surfactants. DOX loaded into cationic niosomes (DOX−Nio) was prepared via thin film hydration method. DOX−Nio was then decorated with a hyaluronic acid (DOX−HA−Nio) via electrostatic interact...

Full description

Saved in:
Bibliographic Details
Published in:Chemistry & biodiversity 2024-02, Vol.21 (2), p.e202301470-n/a
Main Authors: Faddah, Haya, Nsairat, Hamdi, Shalan, Naeem M., El‐Tanani, Mohamed, Alqudah, Dana A., Alshaer, Walhan
Format: Article
Language:English
Subjects:
Breast cancer
Breast Neoplasms - drug therapy
Cell viability
Cytotoxicity
Doxorubicin
Doxorubicin - pharmacology
Electrostatic properties
Entrapment
Female
Freeze drying
Humans
Hyaluronic Acid
Ionic surface active agents
Liposomes
Liquid chromatography
MCF-7 Cells
Niosomes
Self-assembly
Solid tumors
Surfactants
Targeting delivery
Thin films
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3280-50f159fc48c1e61f43b69aef6214e8be03bde5e5ba317bca048c3a2e4ed65cc13
container_end_page n/a
container_issue 2
container_start_page e202301470
container_title Chemistry & biodiversity
container_volume 21
creator Faddah, Haya
Nsairat, Hamdi
Shalan, Naeem M.
El‐Tanani, Mohamed
Alqudah, Dana A.
Alshaer, Walhan
description Doxorubicin (DOX) is widely used against solid tumors. Niosomes are self‐assembled nanocarriers of non‐ionic surfactants. DOX loaded into cationic niosomes (DOX−Nio) was prepared via thin film hydration method. DOX−Nio was then decorated with a hyaluronic acid (DOX−HA−Nio) via electrostatic interaction. DOX−Nio and DOX−HA−Nio displayed a particle size of 120.0±1.02 and 182.9±2.3 nm, and charge of + 35.5±0.15 and −15.6±0.25 mV, respectively, with PDI < 0.3. DOX−HA−Nio showed a good stability regarding size and charge over 4 weeks at 4 °C and maintain their integrity after lyophilization. HPLC results showed a 94.1±4.2 % encapsulation efficiency of DOX with good entrapment and slow, prolonged DOX release even after 48 hrs. Cell viability assay showed an IC50 of 14.26 nM for the DOX−HA−Nio against MCF‐7 cell line with micromolar IC50 results against CD‐44 negative cell lines (NIH/3T3). DOX−HA−Nio was proven to be an effective, targeted nanocarrier for DOX against MCF‐7 cell line.
doi_str_mv 10.1002/cbdv.202301470
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2909091933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2928774299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3280-50f159fc48c1e61f43b69aef6214e8be03bde5e5ba317bca048c3a2e4ed65cc13</originalsourceid><addsrcrecordid>eNqFkblOAzEQhi0EIlwtJbJEQ0GCjz3LZMMlIaAA2pXXO4sc7drB3g2EioIH4Bl5EgyBINGgKeb65tdIP0K7lAwoIexIFuVswAjjhAYxWUEbNKKsT5OErC7rmPXQpnMTz_t5so56PPErf7CBXq8tTIUVrTL6EF9NW9Wo568OC13ic41nqrUGH89E3S3mpsJj82RsVyip9PvLW21ECSVWujX4bO45a7SSeChViTMjWr-7VMaZBhwe3gulXYtHFoRPmdAS7DZaq0TtYOc7b6Hbk-Ob7Kx_cXV6ng0v-pKzhPRDUtEwrWSQSAoRrQJeRKmAKmI0gKQAwosSQggLwWlcSEE8yAWDAMoolJLyLXSw0J1a89CBa_NGOQl1LTSYzuUsJT5oyrlH9_-gE9NZ7b_zFEviOGBp6qnBgpLWOGehyqdWNcLOc0ryT3_yT3_ypT_-YO9btisaKJf4jyEeSBfAo6ph_o9cno3Gd7_iHysKnwE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2928774299</pqid></control><display><type>article</type><title>Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer</title><source>Wiley</source><creator>Faddah, Haya ; Nsairat, Hamdi ; Shalan, Naeem M. ; El‐Tanani, Mohamed ; Alqudah, Dana A. ; Alshaer, Walhan</creator><creatorcontrib>Faddah, Haya ; Nsairat, Hamdi ; Shalan, Naeem M. ; El‐Tanani, Mohamed ; Alqudah, Dana A. ; Alshaer, Walhan</creatorcontrib><description>Doxorubicin (DOX) is widely used against solid tumors. Niosomes are self‐assembled nanocarriers of non‐ionic surfactants. DOX loaded into cationic niosomes (DOX−Nio) was prepared via thin film hydration method. DOX−Nio was then decorated with a hyaluronic acid (DOX−HA−Nio) via electrostatic interaction. DOX−Nio and DOX−HA−Nio displayed a particle size of 120.0±1.02 and 182.9±2.3 nm, and charge of + 35.5±0.15 and −15.6±0.25 mV, respectively, with PDI &lt; 0.3. DOX−HA−Nio showed a good stability regarding size and charge over 4 weeks at 4 °C and maintain their integrity after lyophilization. HPLC results showed a 94.1±4.2 % encapsulation efficiency of DOX with good entrapment and slow, prolonged DOX release even after 48 hrs. Cell viability assay showed an IC50 of 14.26 nM for the DOX−HA−Nio against MCF‐7 cell line with micromolar IC50 results against CD‐44 negative cell lines (NIH/3T3). DOX−HA−Nio was proven to be an effective, targeted nanocarrier for DOX against MCF‐7 cell line.</description><identifier>ISSN: 1612-1872</identifier><identifier>EISSN: 1612-1880</identifier><identifier>DOI: 10.1002/cbdv.202301470</identifier><identifier>PMID: 38161147</identifier><language>eng</language><publisher>Switzerland: Wiley Subscription Services, Inc</publisher><subject>Breast cancer ; Breast Neoplasms - drug therapy ; Cell viability ; Cytotoxicity ; Doxorubicin ; Doxorubicin - pharmacology ; Electrostatic properties ; Entrapment ; Female ; Freeze drying ; Humans ; Hyaluronic Acid ; Ionic surface active agents ; Liposomes ; Liquid chromatography ; MCF-7 Cells ; Niosomes ; Self-assembly ; Solid tumors ; Surfactants ; Targeting delivery ; Thin films</subject><ispartof>Chemistry &amp; biodiversity, 2024-02, Vol.21 (2), p.e202301470-n/a</ispartof><rights>2023 Wiley‐VHCA AG, Zurich, Switzerland</rights><rights>2023 Wiley-VHCA AG, Zurich, Switzerland.</rights><rights>2024 Wiley‐VHCA AG, Zurich, Switzerland</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3280-50f159fc48c1e61f43b69aef6214e8be03bde5e5ba317bca048c3a2e4ed65cc13</cites><orcidid>0000-0001-5916-5879</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38161147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faddah, Haya</creatorcontrib><creatorcontrib>Nsairat, Hamdi</creatorcontrib><creatorcontrib>Shalan, Naeem M.</creatorcontrib><creatorcontrib>El‐Tanani, Mohamed</creatorcontrib><creatorcontrib>Alqudah, Dana A.</creatorcontrib><creatorcontrib>Alshaer, Walhan</creatorcontrib><title>Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer</title><title>Chemistry &amp; biodiversity</title><addtitle>Chem Biodivers</addtitle><description>Doxorubicin (DOX) is widely used against solid tumors. Niosomes are self‐assembled nanocarriers of non‐ionic surfactants. DOX loaded into cationic niosomes (DOX−Nio) was prepared via thin film hydration method. DOX−Nio was then decorated with a hyaluronic acid (DOX−HA−Nio) via electrostatic interaction. DOX−Nio and DOX−HA−Nio displayed a particle size of 120.0±1.02 and 182.9±2.3 nm, and charge of + 35.5±0.15 and −15.6±0.25 mV, respectively, with PDI &lt; 0.3. DOX−HA−Nio showed a good stability regarding size and charge over 4 weeks at 4 °C and maintain their integrity after lyophilization. HPLC results showed a 94.1±4.2 % encapsulation efficiency of DOX with good entrapment and slow, prolonged DOX release even after 48 hrs. Cell viability assay showed an IC50 of 14.26 nM for the DOX−HA−Nio against MCF‐7 cell line with micromolar IC50 results against CD‐44 negative cell lines (NIH/3T3). DOX−HA−Nio was proven to be an effective, targeted nanocarrier for DOX against MCF‐7 cell line.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cell viability</subject><subject>Cytotoxicity</subject><subject>Doxorubicin</subject><subject>Doxorubicin - pharmacology</subject><subject>Electrostatic properties</subject><subject>Entrapment</subject><subject>Female</subject><subject>Freeze drying</subject><subject>Humans</subject><subject>Hyaluronic Acid</subject><subject>Ionic surface active agents</subject><subject>Liposomes</subject><subject>Liquid chromatography</subject><subject>MCF-7 Cells</subject><subject>Niosomes</subject><subject>Self-assembly</subject><subject>Solid tumors</subject><subject>Surfactants</subject><subject>Targeting delivery</subject><subject>Thin films</subject><issn>1612-1872</issn><issn>1612-1880</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkblOAzEQhi0EIlwtJbJEQ0GCjz3LZMMlIaAA2pXXO4sc7drB3g2EioIH4Bl5EgyBINGgKeb65tdIP0K7lAwoIexIFuVswAjjhAYxWUEbNKKsT5OErC7rmPXQpnMTz_t5so56PPErf7CBXq8tTIUVrTL6EF9NW9Wo568OC13ic41nqrUGH89E3S3mpsJj82RsVyip9PvLW21ECSVWujX4bO45a7SSeChViTMjWr-7VMaZBhwe3gulXYtHFoRPmdAS7DZaq0TtYOc7b6Hbk-Ob7Kx_cXV6ng0v-pKzhPRDUtEwrWSQSAoRrQJeRKmAKmI0gKQAwosSQggLwWlcSEE8yAWDAMoolJLyLXSw0J1a89CBa_NGOQl1LTSYzuUsJT5oyrlH9_-gE9NZ7b_zFEviOGBp6qnBgpLWOGehyqdWNcLOc0ryT3_yT3_ypT_-YO9btisaKJf4jyEeSBfAo6ph_o9cno3Gd7_iHysKnwE</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Faddah, Haya</creator><creator>Nsairat, Hamdi</creator><creator>Shalan, Naeem M.</creator><creator>El‐Tanani, Mohamed</creator><creator>Alqudah, Dana A.</creator><creator>Alshaer, Walhan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5916-5879</orcidid></search><sort><creationdate>202402</creationdate><title>Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer</title><author>Faddah, Haya ; Nsairat, Hamdi ; Shalan, Naeem M. ; El‐Tanani, Mohamed ; Alqudah, Dana A. ; Alshaer, Walhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3280-50f159fc48c1e61f43b69aef6214e8be03bde5e5ba317bca048c3a2e4ed65cc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cell viability</topic><topic>Cytotoxicity</topic><topic>Doxorubicin</topic><topic>Doxorubicin - pharmacology</topic><topic>Electrostatic properties</topic><topic>Entrapment</topic><topic>Female</topic><topic>Freeze drying</topic><topic>Humans</topic><topic>Hyaluronic Acid</topic><topic>Ionic surface active agents</topic><topic>Liposomes</topic><topic>Liquid chromatography</topic><topic>MCF-7 Cells</topic><topic>Niosomes</topic><topic>Self-assembly</topic><topic>Solid tumors</topic><topic>Surfactants</topic><topic>Targeting delivery</topic><topic>Thin films</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faddah, Haya</creatorcontrib><creatorcontrib>Nsairat, Hamdi</creatorcontrib><creatorcontrib>Shalan, Naeem M.</creatorcontrib><creatorcontrib>El‐Tanani, Mohamed</creatorcontrib><creatorcontrib>Alqudah, Dana A.</creatorcontrib><creatorcontrib>Alshaer, Walhan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Chemistry &amp; biodiversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faddah, Haya</au><au>Nsairat, Hamdi</au><au>Shalan, Naeem M.</au><au>El‐Tanani, Mohamed</au><au>Alqudah, Dana A.</au><au>Alshaer, Walhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer</atitle><jtitle>Chemistry &amp; biodiversity</jtitle><addtitle>Chem Biodivers</addtitle><date>2024-02</date><risdate>2024</risdate><volume>21</volume><issue>2</issue><spage>e202301470</spage><epage>n/a</epage><pages>e202301470-n/a</pages><issn>1612-1872</issn><eissn>1612-1880</eissn><abstract>Doxorubicin (DOX) is widely used against solid tumors. Niosomes are self‐assembled nanocarriers of non‐ionic surfactants. DOX loaded into cationic niosomes (DOX−Nio) was prepared via thin film hydration method. DOX−Nio was then decorated with a hyaluronic acid (DOX−HA−Nio) via electrostatic interaction. DOX−Nio and DOX−HA−Nio displayed a particle size of 120.0±1.02 and 182.9±2.3 nm, and charge of + 35.5±0.15 and −15.6±0.25 mV, respectively, with PDI &lt; 0.3. DOX−HA−Nio showed a good stability regarding size and charge over 4 weeks at 4 °C and maintain their integrity after lyophilization. HPLC results showed a 94.1±4.2 % encapsulation efficiency of DOX with good entrapment and slow, prolonged DOX release even after 48 hrs. Cell viability assay showed an IC50 of 14.26 nM for the DOX−HA−Nio against MCF‐7 cell line with micromolar IC50 results against CD‐44 negative cell lines (NIH/3T3). DOX−HA−Nio was proven to be an effective, targeted nanocarrier for DOX against MCF‐7 cell line.</abstract><cop>Switzerland</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38161147</pmid><doi>10.1002/cbdv.202301470</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5916-5879</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1612-1872
ispartof Chemistry & biodiversity, 2024-02, Vol.21 (2), p.e202301470-n/a
issn 1612-1872
1612-1880
language eng
recordid cdi_proquest_miscellaneous_2909091933
source Wiley
subjects Breast cancer
Breast Neoplasms - drug therapy
Cell viability
Cytotoxicity
Doxorubicin
Doxorubicin - pharmacology
Electrostatic properties
Entrapment
Female
Freeze drying
Humans
Hyaluronic Acid
Ionic surface active agents
Liposomes
Liquid chromatography
MCF-7 Cells
Niosomes
Self-assembly
Solid tumors
Surfactants
Targeting delivery
Thin films
title Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T10%3A54%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preparation,%20Optimization%20and%20In%20vitro%20Evaluation%20of%20Doxorubicin%E2%80%90loaded%20into%20Hyaluronic%20Acid%20Coated%20Niosomes%20Against%20Breast%20Cancer&rft.jtitle=Chemistry%20&%20biodiversity&rft.au=Faddah,%20Haya&rft.date=2024-02&rft.volume=21&rft.issue=2&rft.spage=e202301470&rft.epage=n/a&rft.pages=e202301470-n/a&rft.issn=1612-1872&rft.eissn=1612-1880&rft_id=info:doi/10.1002/cbdv.202301470&rft_dat=%3Cproquest_cross%3E2928774299%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3280-50f159fc48c1e61f43b69aef6214e8be03bde5e5ba317bca048c3a2e4ed65cc13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2928774299&rft_id=info:pmid/38161147&rfr_iscdi=true